Untitled

Introduction to Medicinal Chemistry

Presented by: Gebretekle G., B. Pharm., MSc in Medicinal Chemistry
Affiliation: Pharmaceutical Analysis Unit, Department of Pharmacy, College of Medicine and Health Sciences, Adigrat University

Objectives

Upon completion of this session, students will be able to:

  • Define Medicinal Chemistry and understand its scope
  • Describe the relationships between Medicinal Chemistry and other disciplines
  • Identify the source and classification of drugs
  • Practice drug nomenclature based on different nomenclature systems
  • Understand methods for designing analogs

Introduction to Medicinal Chemistry

1) Definition of Medicinal Chemistry

  • Medicinal Chemistry involves:
    • Invention, discovery, identification, development, and interpretation of mechanisms of action of biologically active compounds at the molecular level.
    • Design and synthesis of compounds as potential new drugs, often referred to as the generation of new chemical entities (NCEs) for medicinal purposes.
    • Emphasizes the chemistry of receptors.

1.1) Impact of Chemical Structure

  • It studies how the chemical structure and physicochemical properties of a molecule influence drug pharmacokinetics and pharmacological properties.
    • Physicochemical properties: Influence of functional groups (FGs) on hydrophilicity, partitioning coefficient, stereochemistry, etc.
  • Total concern for systematic modification of drug molecules to determine how changes affect biological activities.
    • Structure Activity Relationships (SAR): Relation of structural features of molecules with biological activity.

1.2) Main Stages of Medicinal Chemistry

  1. Lead Discovery:
    • New active drugs are identified and prepared from natural sources, chemical reactions, or biotechnological processes.
  2. Lead Optimization:
    • Enhancing lead compounds to boost potency and selectivity while reducing toxicity.
  3. Drug Candidate Development:
    • Optimization for bulk production, modification of pharmacokinetics and pharmaceutical properties for clinical use.

Related Disciplines in Medicinal Chemistry

  • Key Fields:
    • Organic Chemistry
    • Combinatorial Chemistry
    • Computational Chemistry
    • Biochemistry
    • Analytical Chemistry
    • X-ray Crystallography
    • NMR Spectroscopy
    • Pharmacognosy
    • Molecular Modelling
    • Genomics & Proteomics
    • Bioinformatics
    • Immunology
    • Molecular Biology
    • Pharmacology
    • Microbiology
  • Medicinal Chemistry resides at the interface of chemistry and biology.

Combinatorial Chemistry

  • Involves rapid synthesis of large collections of compounds, known as compound libraries.
  • Accelerates the drug discovery process.

Computational Chemistry

  • Utilizes mathematical methods in computers to produce information regarding various properties of molecules.
  • X-ray Crystallography:
    • Essential for studying crystal structures of target molecules, providing vital 3D structural parameters necessary for rational drug design.

Definition and Classification of Drugs

1.3) Definition of a Drug

  • A drug is defined as a single chemical entity utilized for:
    • Diagnosis
    • Prevention
    • Treatment of symptoms
    • Cure of diseases
    • Broader definition: "All chemicals other than food that affect living processes".

1.4) Classification of Drugs

  1. Based on Origin:
    • Natural (plants, animals, minerals, microorganisms)
    • Synthetic
    • Semi-synthetic
  2. Based on Chemical Structure:
    • Steroids, penicillins, quinolones, azoles, etc.
  3. Based on Pharmacological Action:
    • Antivirals, antianginals, diuretics, bronchodilators, antibacterials.
  4. Based on Site of Action:
    • CNS drugs, CVS drugs, GIT drugs, chemotherapeutic agents, etc.

1.5) Nomenclature of Drugs

  • Code Number/Name:
    • Assigned by manufacturers before an approved name is coined (e.g., RO15-1788 later became flumazenil).
  • Chemical Name:
    • May not be suitable for clinical use, e.g., N-acetyl-p-aminophenol for paracetamol.
  • Proprietary/Brand/Trade Name:
    • Chosen by the pharmaceutical company; one drug may have several proprietary names (e.g., atenolol has names like Atecort, Aten, Betacard).
  • Non-Proprietary/Generic/Official Name:
    • The approved official name in pharmacopeia, e.g., paracetamol or acetaminophen.

1.6) Sources of Drugs

  • Natural Sources (e.g., from animals for insulin):
    • Animal (8.7%): Insulin, gonadotropins, thyroid extracts.
    • Mineral (9.1%): Calcium, potassium, phosphorus, sodium, magnesium, iron.
    • Plant (11.1%): Vincristine, taxol, digoxin, quinine, reserpine.
    • Microorganisms: Antibiotics such as penicillin, streptomycin, tetracycline.
  • Synthetic Sources (48.9%):
    • Widely used for cost efficiency and efficacy (e.g., aspirin, paracetamol).
  • Semi-Synthetic Sources (9.5%):
    • Recombinant DNA technology (e.g., insulin).
  • Biosynthetic:
    • Drugs that are complex polypeptides, difficult and costly to synthesize in a lab (e.g., erythropoietin, hepatitis vaccine).

Receptors and Drug Action

1.7) Understanding Receptors

  • A receptor is a specific chemical component of the cell that interacts with a drug to create pharmacological effects.
  • Receptors include proteins, glycoproteins (e.g., G-protein coupled receptors), and sometimes nucleic acids.

Types of Receptors

I) Ligand-Gated Ion Channels
  • Membrane-bound receptors directly linked to ion channels composed of five protein subunits that traverse the membrane four times.
  • Agonists open the channel causing depolarization or hyperpolarization, with response time measured in milliseconds.
  • Examples include nicotine, glutamate, GABA-A, and 5-HT3 receptors.
II) G-Protein Coupled Receptors (GPCRs)/Metabotropic Receptors
  • Contains binding sites for neurotransmitters (extracellularly) and G-protein.
  • Ligand binding alters receptor shape, opening a binding site for G-proteins; the G-protein fragments then interact with enzymes to propagate the signal.
  • Significant as 30% of drugs act via these receptors (e.g., muscarinic, histaminic, adrenergic, dopaminergic receptors).
III) Tyrosine Kinase-Linked Receptors
  • Membrane-bound receptors with:
    • Extracellular domains that bind ligands at the N-terminus.
    • Intracellular domains with enzymatic functions (tyrosine kinase activity at the C-terminus).
  • Ligand binding activates the receptor causing phosphorylation of tyrosine residues.
  • Examples include receptors for insulin and various cytokines.
IV) Intracellular/Nuclear Receptors
  • Located in the cytosol; require hydrophobic ligands that can cross membranes.
  • Activated receptors translocate to the nucleus to initiate gene transcription, operating over hours to days—slower than other receptors.
  • Zinc ions stabilize the DNA binding region.
  • Examples include receptors for steroid hormones, thyroid hormones, vitamin D, and retinoid.

Drug-Receptor Interactions

Covalent Interactions

  • Formed when a drug atom and receptor atom share a pair of electrons, resulting in essentially irreversible engagement under biological conditions.
  • Rare under non-toxic conditions due to the reversible nature of most interactions.
  • Example: Bond formed between phenoxybenzamine and its receptor.

Ionic Interactions

  • Driven by attraction between oppositely charged receptor sites and ionized drug groups, representing strong electrostatic interactions.
  • More common than covalent interactions, especially between charged ionic molecules.
  • Receptors with ionizable groups at physiological pH interact with ionized drugs (e.g., acetylcholine).

Hydrogen Bonding

  • Created when hydrogen bonded to an electronegative atom possesses a positive charge and is attracted to another atom with a relative negative charge.
  • Critical for hydrophilicity; many hydrogen bonds grant stability to drug-receptor interactions.

Van der Waals Attractions

  • The weakest intermolecular forces occurring between nonpolar groups, which are highly distance and temperature-dependent.

Hydrophobic Interactions

  • Result from interactions between nonpolar drug and receptor groups, with the interaction generally being weak but significant for molecular functions.
    • Notable in interactions between lipophilic drugs and lipid components of membranes or with nonpolar receptor regions.

1.8) Drug Design

  • The drug discovery process begins with identifying hits, which are substances with preferential activity for a target, characterized by:
    • Reproducible activity in relevant bioassays.
    • Confirmed structure and high purity.
    • Target specificity and novelty.
    • Chemically tractable structure.

Hit Validation Criteria

  • Must be active in vivo (in tissue), have no major human toxicity, lack chemically reactive functions, provide patent potential, and present analogs that illustrate clear SARs.
  • Conversion of hits to leads is termed Hits-to-Leads (H2L) or lead generation.

Lead Compounds

  • A lead compound is recognized for its strong potential to transition into drug development, characterized by satisfactory properties (potency, selectivity, PK, physicochemical properties, novelty, and low toxicity).
  • The optimization of lead compounds is grounded in SAR insights to enhance affinity, geometry, and stability.

Sources of Lead Compounds

I) Screening of Natural Products

  • Early chemists searched for new medicines through plant sources with pharmacological actions.
    • Natural source examples include papaver somniferum and erythroxylon coca.

II) Random Screening of Synthetic Organic Compounds

  • Introduced in the 1930s after sulphonamides' discovery, which involved testing vast libraries of chemicals (often up to 500,000 compounds for a single activity).
    • Amantadine as an anti-influenza-A drug originated from broad antiviral screening, though this method is seen as inefficient.
    • High-throughput screening (HTS) systems enhance efficiency by using robotics and combinatorial chemistry.

III) Rational Approach

  • Based on knowledge of the drug target, where understanding geometry and chemistry of the active site leads to compound design (e.g., Captopril).
  • Steps include identifying disease, target, bioassay, and lead optimization, ultimately leading to preclinical studies and clinical trials.

IV) Enhancing Side Effects of Existing Drugs

  • Initial development of phenothiazine antipsychotics stemmed from improving antihistamine properties.
    • Notable drugs transitioned from sedative agents to antipsychotics (e.g., promethazine to chlorpromazine).

V) Serendipity

  • Accidental discovery cases include penicillin from contaminated Staphylococcus cultures or phenylbutazone's original function as a solubilizer for aminopyrine.

VI) Drug Metabolite as Leads

  • Metabolites like acetaminophen can serve as new drug leads. They may also exhibit better profiles in terms of absorption, action duration, and reduced toxicity.

VII) Analog Designing

  • Aim to create new drugs with improved properties over prototypes.
    • Analog drugs are termed “me-too drugs,” retaining similarities with prototypes in chemical and pharmacological aspects.
    • Example: Simvastatin is a me-too drug more effective than its prototype, lovastatin.

Molecular Design Considerations

I) Branching

  • Can affect lipophilicity due to hydrogen bonding stability and could significantly alter pharmacological activity if hydrocarbons are critical for receptor interactions.
    • Example: Differences in activity between promethazine (H1-blocker) and promazine (antipsychotic) mainly hinge on their alkyl amine side chains.

II) Rigidification

  • Complexifying a drug molecule prevents additional conformations, potentially enhancing receptor fit and activity.
    • Example: Etorphine, a rigidified morphine derivative, shows significantly higher potency and affinity for analgesic receptors.

III) Ring Expansion or Contraction

  • Altering ring sizes can shift binding groups' relative positions, potentially improving receptor interactions.

IV) Ring Variations

  • Creating selective β-blockers through aromatic ring substitution improves receptor binding efficiency.

Molecular Manipulation Techniques

I) Molecular Addition

  • Involves associating different moieties via weak forces such as electrostatic attraction and hydrogen bonding.

II) Molecular Simplification

  • Involves removing non-essential structural parts while retaining activity to create simpler, more synthesize-friendly compounds.
    • Example: Procaine derived from cocaine; morphine has undergone simplification for analog generation with fewer side effects.

III) Molecular Replication

  • Involves associating identical moieties through covalent bonding.

IV) Molecular Hybridization

  • Similar to replication but involves different moieties combined through covalent bonds.

Special Processes

  • Alterations to increase or decrease a molecule’s dimension or flexibility:
    • Ring closure (e.g., Nefopam) versus ring opening (e.g., Diethylstilbesterol).

V) Homologation

  • Adjusting structure through incremental changes (e.g., methyl to ethyl) may modulate agonist or antagonist qualities.

VI) Introduction of Double Bonds

  • Can lead to geometric isomer formations with differing biological activities and alteration of physicochemical properties.

VII) Chiral Modification

  • Changes to stereochemistry can dramatically influence pharmacological activity (e.g., ephedrine vs. pseudoephedrine).

VIII) Introduction/Removal of Bulky Groups

  • Altering bulky groups affects physical and chemical properties significantly impacting drug efficacy.

IX) Group Replacement and Bioisosterism

  • Alteration of chemical properties will employ isosteric replacement leading to the identification of bioisosters with similar biological activities.

Drug Discovery Process Overview

  1. FDA Approved Drugs: 1
  2. Clinical Trials: 250 compounds
  3. Preclinical Studies: 10,000 compounds
  4. Drug Discovery: This sequence indicates that the number of compounds at each developmental step decreases as the process narrows down.

Conclusion: Stereochemistry and Drug Action

  • The study of three-dimensional molecular structures, essential for specific enzyme-substrate interactions, affecting both metabolism and pharmacological outcomes.
  • Isomers:
    • Same molecular formula but differ in atom arrangements, leading to different properties.

Classification of Isomers

  • Constitutional Isomers: Same atom connectivity but differ in structural arrangement.
  • Stereoisomers: Characterized by different spatial arrangements.
  • Enantiomers: Chiral and optically active; properties differ significantly (e.g., dextromethorphan vs. levomethorphan).
  • Diacetyl Isomers: Can exist as non-mirror images (diastereomers) when chiral centers are present.

The End

Note: This document encompasses comprehensive details from the session on Medicinal Chemistry to ensure a deep understanding and facilitate effective study.